Morgan Stanley Boosts Zoetis Inc. (ZTS) Price Target to $70.00
Several other research firms have also weighed in on ZTS. Cantor Fitzgerald set a $75.00 target price on Zoetis and gave the stock a buy rating in a report on Monday, August 14th. Cowen and Company set a $70.00 target price on Zoetis and gave the stock a buy rating in a report on Monday, July 17th. Stifel Nicolaus restated a buy rating and issued a $65.00 target price on shares of Zoetis in a report on Friday, July 21st. Goldman Sachs Group, Inc. (The) restated a neutral rating and issued a $62.00 target price on shares of Zoetis in a report on Monday, August 7th. Finally, BidaskClub lowered Zoetis from a hold rating to a sell rating in a report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $67.06.
Shares of Zoetis (ZTS) opened at $68.69 on Friday. The stock has a market capitalization of $33,471.81, a PE ratio of 31.51, a PEG ratio of 2.05 and a beta of 1.02. The company has a debt-to-equity ratio of 2.13, a quick ratio of 1.17 and a current ratio of 2.01. Zoetis has a 1-year low of $48.24 and a 1-year high of $68.80.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 66.15% and a net margin of 18.29%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.52 EPS. sell-side analysts anticipate that Zoetis will post 2.35 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Thursday, November 9th will be issued a dividend of $0.105 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.61%. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.
Several hedge funds have recently modified their holdings of ZTS. Janus Henderson Group PLC lifted its holdings in shares of Zoetis by 7,717.4% during the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock worth $362,372,000 after buying an additional 5,734,776 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Zoetis by 55.4% during the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock worth $646,905,000 after buying an additional 3,695,449 shares during the last quarter. Waddell & Reed Financial Inc. increased its position in shares of Zoetis by 65.9% during the first quarter. Waddell & Reed Financial Inc. now owns 5,434,371 shares of the company’s stock valued at $290,033,000 after purchasing an additional 2,157,803 shares during the period. BlackRock Inc. increased its position in shares of Zoetis by 3.9% during the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after purchasing an additional 1,412,829 shares during the period. Finally, AJO LP increased its position in shares of Zoetis by 4,506.8% during the second quarter. AJO LP now owns 1,271,425 shares of the company’s stock valued at $79,311,000 after purchasing an additional 1,243,826 shares during the period. Institutional investors own 93.04% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.